Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy

Urologia Internationalis

Volumn 83, Issue 4, 2009, Pages 463-470

  Lin, Han Ching ^a,b   Liu, Chia Chu ^a   Kang, Wan Yi ^c   Yu, Chia Cheng ^d   Wu, Tony T ^d   Wang, Jyh Seng ^e   Wu, Wen Jeng ^a,g   Huang, Chun Hsiung ^a,g   Wu, Ming Tsang ^c,f   Huang, Shu Pin ^a,g,h  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b TIAN SHENG MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Division of Urology   (Canada)

^e KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f Graduate Institute of Occupational Safety and Health   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^h KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Cytokine; Genetic polymorphisms; Prostate cancer; Prostate specific antigen

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; COVARIANCE; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; GENOTYPE; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECURRENCE RISK;

AGED; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 72049122396     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000251189     Document Type: Article

References (32)

1. American Joint Committee on Cancer Staging Manual, ed 5. Philadelphia, Lippincott Raven, 1997.
2. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64.
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-914.
4. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439. (Pubitemid 41124175)
5. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867.
6. Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83.
7. Kobayashi M, Nukui A, Morita T: Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. Urol Int 2008; 80: 186-192.
8. Mahmud S, Franco E, Aprikian A: Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and metaanalysis. Br J Cancer 2004; 90: 93-99.
9. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 127-129.
10. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-3372.
11. Sun J, Hedelin M, Zheng SL, Adami HO, Bensen J, Augustsson-Balter K, Chang B, Adolfsson J, Adams T, Turner A, Meyers DA, Isaacs WB, Xu J, Gronberg H: Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 1677-1679.
12. Wu HC, Chang CH, Chen HY, Tsai FJ, Tsai JJ, Chen WC: P53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int 2004; 73: 41-46.
13. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB: Genetic polymorphisms of interleukin-1b (IL-1b), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66: 4525-4530.
14. Giri D, Ozen M, Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 2159-2165. (Pubitemid 33104270)
15. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12: 33-40.
16. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophagederived mediator of angiogenesis. Science 1992; 258: 1798-1801.
17. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000; 6: 2104-2119. (Pubitemid 30305111)
18. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM: Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999; 154: 1503-1512.
19. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, Vessella RL, Ralph D: Interleukin-serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999; 53: 139-147.
20. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-receptor. Annu Rev Immunol 2001; 19: 683-765.
21. Stearns ME, Rhim J, Wang M: Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase- 1 and inhibition of matrix metallo - proteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999; 5: 189-196.
22. Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, Yu CC, Wu TT, Huang CH, Wu WJ, Chou YH, Wu MT: Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate- specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007; 13: 6632-6638.
23. Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT: Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006; 119: 1902-1907.
24. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical diseasefree and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565.
25. Freedland SJ, Sutter ME, Dorey F, Aronson WJ: Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 365-369.
26. Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA: Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004; 172: 129-132.
27. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P: Polymorphic haplotypes of the interleukin-10 5 - flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42: 1101-1108.
28. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 1993; 54: 1-78.
29. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z: Immunohistochemical localization of interleukin-and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191: 239-244.
30. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41: 127-133.
31. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-146. (Pubitemid 27020343)
32. Hull J, Thomson A, Kwiatkowski D: Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000; 55: 1023-1027.